Cancer biomarkers market for TMB, MSI / MMR and TILs is estimated to be worth USD 860 million

The report features an extensive study of the current landscape and future outlook of the immuno-oncology biomarker testing market (focusing particularly on TMB, MSI and TILs (CD3+, CD4+, CD8+, FOXP3+)). It provides an in-depth analysis, highlighting the capabilities of the various companies engaged in this domain. Amongst various elements, the report includes:
 A detailed analysis of ongoing, biomarker-based clinical trials initiated by big pharmaceutical companies.
 An analysis of the landscape of companies offering testing services for cancer biomarkers, namely TMB, MSI / MMR and TILs (including CD3+, CD4+, CD8+ and FOXP3+).
 An insightful 2X2 representation of the results of a detailed competitiveness analysis of various tests (segregated across different biomarker groups).
 Elaborate profiles of leading analytical testing service providers focused on immuno-oncology biomarkers (shortlisted based on strength of service portfolio).
 One of the key objectives of the report was to estimate the existing cancer biomarkers market size and potential growth opportunities for cancer biomarkers market over the coming decade